Evidence map›Paper›PMID 41282197›Full record

ArticleResearch square2025

Effective imaging and treatment of Acute Myeloid Leukemia with radiotheranostics targeting the activated conformation of integrin-βeta2.

Anju Wadhwa, Haley Johnson, Kondapa Naidu Bobba, Anil P Bidkar, Ellis Mayne, Sham Rampersaud, Kamal Mandal, Abhilash Barpanda, Sanjana Prudhvi, Amrik S Kang and 19 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Anju WadhwaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Haley JohnsonUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Kondapa Naidu BobbaDepartment of Nuclear Engineering, University of Tennessee-Knoxville, Knoxville, Tennessee 37996, United States.
Anil P BidkarDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0003-1249-1081
Ellis MayneDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Sham RampersaudUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.ORCID https://orcid.org/0000-0001-7473-4144
Kamal MandalAnimal Biotechnology, Gujarat Biotechnology University, Gujarat, Ahmedabad, India.
Abhilash BarpandaUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Sanjana PrudhviUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Amrik S KangUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.ORCID https://orcid.org/0000-0003-0445-5654
Nancy GreenlandDepartment of Pathology, University of California, San Francisco, California 94110, United States.
Dana BalitzerDepartment of Pathology, University of California, San Francisco, California 94110, United States.
Robin PeterUniversity of California, Berkeley, California, United States.ORCID https://orcid.org/0009-0003-3448-8462
Athira RaveendranDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Shubhankar NaikUniversity of California, Berkeley, California, United States.ORCID https://orcid.org/0000-0002-9640-1188
Megha BasakDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Corynn KasapDepartment of Medicine, Division of Hematology/Oncology University of California, San Francisco, California 94110, United States.ORCID https://orcid.org/0000-0002-3667-8097
Juwita WernerUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Marina López-ÁlvarezDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0001-5794-5951
Sang Hee LeeDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0001-8578-9968
Veronica SteriDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Jarret J AdamsSchool of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada N2G 1C5.
Sachdev S SidhuSchool of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada N2G 1C5.
David M WilsonDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Youngho SeoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0001-5908-6636
Henry F VanBrocklinDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Aaron C LoganDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0002-1179-5879
Arun P WiitaUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.ORCID https://orcid.org/0000-0002-7465-6964
Robert R FlavellDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.ORCID https://orcid.org/0000-0002-8694-1199

Funding

Selective treatment of acute myeloid leukemia with radioimmunotherapies targeting the active conformation of integrin beta-2R01CA297845 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Robert Richard Flavell, Arun P. Wiita · 2025 to 2026
$1.4M
High-throughput microPET/CT at UCSF Preclinical Imaging CoreS10OD034286 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEO, YOUNGHO · 2023 to 2023
$662k
NCI NIH HHS R01 CA297845NIH HHS S10 OD034286
6 · The paper itself

Abstract

There remains an unmet clinical need for improved treatment strategies in Acute Myeloid Leukemia (AML). Although radiopharmaceutical therapies targeting non-cancer-selective antigens have shown promise in AML, their clinical utility is often limited by prolonged bone marrow suppression. Using a unique proteomics-based strategy, we recently identified the active conformation of integrin-β2 (aITGB2) as a novel, tumor-selective target for AML. Importantly, this conformational epitope is expressed widely on AML cells but minimally on normal marrow progenitors/healthy tissues. Here we first confirmed widespread aITGB2 expression on AML tumors that was largely independent of tumor genotype or prior therapeutic regimen. We developed diagnostic and therapeutic radiopharmaceuticals targeting aITGB2 utilizing a conformation-specific antibody (clone 7065). PET/CT imaging with

Identifiers

PMID41282197
PMCPMC12636732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.